Mereo BioPharma Group (MREO) Expected to Announce Earnings on Wednesday

Mereo BioPharma Group (NASDAQ:MREO) is expected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 21st. Analysts expect Mereo BioPharma Group to post earnings of ($0.01) per share for the quarter.

Mereo BioPharma Group (NASDAQ:MREO) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). On average, analysts expect Mereo BioPharma Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Mereo BioPharma Group Price Performance

Shares of NASDAQ:MREO opened at $2.29 on Tuesday. The firm has a fifty day moving average price of $2.31 and a two-hundred day moving average price of $2.95. The company has a market cap of $364.11 million, a price-to-earnings ratio of -32.71 and a beta of 0.53. Mereo BioPharma Group has a one year low of $1.58 and a one year high of $5.02.

Institutional Investors Weigh In On Mereo BioPharma Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. lifted its position in Mereo BioPharma Group by 0.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,125,920 shares of the company’s stock valued at $4,783,000 after buying an additional 6,068 shares during the period. Woodline Partners LP increased its stake in shares of Mereo BioPharma Group by 53.2% in the 1st quarter. Woodline Partners LP now owns 947,986 shares of the company’s stock worth $2,133,000 after acquiring an additional 329,202 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Mereo BioPharma Group by 62.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,569,100 shares of the company’s stock worth $3,530,000 after acquiring an additional 604,200 shares in the last quarter. 62.83% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on MREO. Needham & Company LLC restated a “buy” rating and set a $7.00 price target on shares of Mereo BioPharma Group in a research report on Tuesday, May 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Tuesday, March 18th. Finally, JPMorgan Chase & Co. started coverage on shares of Mereo BioPharma Group in a research report on Thursday, March 27th. They set an “overweight” rating and a $7.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Mereo BioPharma Group has a consensus rating of “Buy” and an average target price of $7.71.

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.